Israeli scientists launch world-first clinical trial for experimental pancreatic cancer treatment

Israeli scientists have launched the world's first clinical trial for an experimental pancreatic cancer treatment that uses RNA molecules to silence mutated KRAS genes. The trial will test the therapy alongside standard treatment in patients with locally advanced pancreatic cancer. Pancreatic cancer is notoriously difficult to treat, with a five-year survival rate of around 10%, and KRAS mutations are present in over 90% of cases. The approach, developed by researchers at Tel Aviv University and the Sheba Medical Center, aims to target the genetic driver of the disease directly. If successful, this could represent a significant breakthrough in oncology, potentially extending survival and improving quality of life for patients. The trial is currently recruiting participants and is expected to yield initial results within two years.

Global Impact

Pancreatic cancer is one of the deadliest cancers globally, with over 460,000 deaths per year. A successful therapy targeting KRAS mutations would have enormous economic and social impact, potentially saving hundreds of thousands of lives and reducing healthcare costs associated with late-stage care.